Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Phase 1

Withdrawn

Conditions: Acute Graft Versus Host Disease
Gastrointestinal Tract Acute Graft Versus Host Disease
Severe Gastrointestinal Tract Acute Graft Versus Host Disease
Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease

Interventions: Drug: Fecal Microbiota Transplantation Capsule

First Posted Date: 2020-02-21

Last Posted Date: 2023-09-22

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT04280471

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Stage IVA Prostate Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Drug: Gallium Ga 68 Gozetotide
Procedure: Positron Emission Tomography

First Posted Date: 2020-02-21

Last Posted Date: 2022-09-21

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT04279561

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma
Progressive Disease
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma

Interventions: Biological: Anakinra
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate

First Posted Date: 2019-12-20

Last Posted Date: 2024-12-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT04205838

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Phase 1

Recruiting

Conditions: Recurrent Glioblastoma

Interventions: Biological: Dendritic Cell Tumor Cell Lysate Vaccine
Other: Placebo Administration
Biological: Pembrolizumab
Drug: Poly ICLC

First Posted Date: 2019-12-17

Last Posted Date: 2024-10-16

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT04201873

Locations: 🇺🇸
Quan, Los Angeles, California, United States

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Phase 1

Terminated

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Progesterone Receptor Negative
Anatomic Stage IB Breast Cancer AJCC v8
Invasive Ductal Carcinoma, Not Otherwise Specified
Prognostic Stage 0 Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Biological: Talimogene Laherparepvec

First Posted Date: 2019-12-04

Last Posted Date: 2023-08-15

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT04185311

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Early Phase 1

Recruiting

Conditions: Gastric Carcinoma
Pancreatic Carcinoma
Uterine Corpus Cancer
Colon Carcinoma
Kidney Carcinoma
Lung Carcinoma
Solid Neoplasm
Head and Neck Carcinoma
Breast Carcinoma
Esophageal Carcinoma

Interventions: Procedure: Computed Tomography
Radiation: Gallium Ga 68 FAPi-46
Radiation: Gallium Ga 68-labeled PSMA-11
Procedure: Positron Emission Tomography
Radiation: 18F-FDG

First Posted Date: 2019-11-01

Last Posted Date: 2024-04-15

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT04147494

Locations: 🇺🇸
Ethan Lam, Los Angeles, California, United States

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Pathologic Stage IIIC Cutaneous Melanoma AJCC V8
Pathologic Stage IV Cutaneous Melanoma AJCC V8
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Uveal Melanoma
Acral Melanoma
Neuroendocrine Tumors
Paraganglioma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Fludeoxyglucose F-18
Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2019-10-08

Last Posted Date: 2024-12-11

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT04119024

Locations: 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
KRAS Protein Variant
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Biological: Cetuximab
Drug: Cisplatin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy

First Posted Date: 2019-09-27

Last Posted Date: 2023-06-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT04106362

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

OsteoCrete in Filling Bone Voids in Participants With Bone Voids or Defects

Not Applicable

Completed

Conditions: Health Status Unknown

Interventions: Other: Magnesium-based Bone Void Filler

First Posted Date: 2019-08-28

Last Posted Date: 2022-09-23

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT04069923

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Stereotactic Radiation Therapy Before Surgery for the Treatment of Resectable Brain Metastases

Not Applicable

Withdrawn

Conditions: Malignant Neoplasm, Brain
Brain Tumor

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Radiosurgery
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2019-08-28

Last Posted Date: 2022-01-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT04069910

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy